Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

NEXT STORY
Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Melanoma at ASCO 2021 Annual Meeting
PREV STORY
G1 Therapeutics Presents Phase 1 Data at ASCO Describing Favorable Safety Profile and Evidence of Antitumor Activity of Rintodestrant Combined with Palbociclib in Patients with ER+/HER2- Advanced Breast Cancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Antimicrobial Susceptibility Testing Market Worth $5.09 billion by 2027 – Exclusive Report by Meticulous Research®

author_avatar
NASDAQ Market News

Type 1 Diabetes Market Size is Projected to Reach USD 2,800 Million by 2026, Globally: Facts & Factors

author_avatar
NASDAQ Market News

Stemline Therapeutics Announces that FDA Accepts ELZONRIS™ Biologics License Application (BLA) and Grants Priority Review

Conference call on BLA acceptance and commercial readiness scheduled for Monday, August 13, 2018 ...

author_avatar
NASDAQ Market News